The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Impel Pharmaceuticals Inc. on February 2, 2024. The debtor has been authorized to sell substantially all its assets to JN Bidco LLC, for a purchase price of $17.5 million in cash. The debtor did not receive any other competing bids for the purchase of its assets and therefore JN Bidco LLC emerged as the winning bidder.
IPI Legacy Liquidation Co
Equities
IMPL
US45258K1097
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 USD | 0.00% | 0.00% | -87.85% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 05 | North American Morning Briefing : Investors on -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IMPL Stock
- News IPI Legacy Liquidation Co
- Motion for Asset Sale Approved for Impel Pharmaceuticals Inc.